JP2015531348A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015531348A5 JP2015531348A5 JP2015531567A JP2015531567A JP2015531348A5 JP 2015531348 A5 JP2015531348 A5 JP 2015531348A5 JP 2015531567 A JP2015531567 A JP 2015531567A JP 2015531567 A JP2015531567 A JP 2015531567A JP 2015531348 A5 JP2015531348 A5 JP 2015531348A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide according
- peptide
- amyloid
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 8
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- 150000008574 D-amino acids Chemical class 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000001784 detoxification Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002703 mutagenesis Methods 0.000 claims 1
- 231100000350 mutagenesis Toxicity 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 238000010647 peptide synthesis reaction Methods 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102012108598.6A DE102012108598A1 (de) | 2012-09-14 | 2012-09-14 | Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung |
| DE102012108598.6 | 2012-09-14 | ||
| PCT/EP2013/068992 WO2014041115A2 (de) | 2012-09-14 | 2013-09-13 | Neue, von d3 abgeleitete d-enantiomere peptide und deren verwendung |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018098517A Division JP6611858B2 (ja) | 2012-09-14 | 2018-05-23 | Ｄ３から誘導されたｄ−エナンチオマーの新規ペプチド及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015531348A JP2015531348A (ja) | 2015-11-02 |
| JP2015531348A5 true JP2015531348A5 (enExample) | 2016-11-04 |
| JP6345670B2 JP6345670B2 (ja) | 2018-06-20 |
Family
ID=49354628
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015531567A Active JP6345670B2 (ja) | 2012-09-14 | 2013-09-13 | Ｄ３から誘導されたｄ−エナンチオマーの新規ペプチド及びその使用 |
| JP2018098517A Active JP6611858B2 (ja) | 2012-09-14 | 2018-05-23 | Ｄ３から誘導されたｄ−エナンチオマーの新規ペプチド及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018098517A Active JP6611858B2 (ja) | 2012-09-14 | 2018-05-23 | Ｄ３から誘導されたｄ−エナンチオマーの新規ペプチド及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20150307552A1 (enExample) |
| EP (2) | EP2895867B1 (enExample) |
| JP (2) | JP6345670B2 (enExample) |
| CN (2) | CN107556375A (enExample) |
| DE (1) | DE102012108598A1 (enExample) |
| DK (2) | DK2895867T3 (enExample) |
| ES (2) | ES2768264T3 (enExample) |
| PL (1) | PL3346273T3 (enExample) |
| WO (1) | WO2014041115A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102012108598A1 (de) * | 2012-09-14 | 2014-04-10 | Forschungszentrum Jülich GmbH | Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung |
| DE102015003503A1 (de) * | 2015-03-20 | 2016-09-22 | Forschungszentrum Jülich GmbH | Spezifisch Amyloid-Beta bindende Peptide und deren Verwendung für die Therapie und Diagnose der Alzheimerschen Demenz |
| DE102015003676A1 (de) | 2015-03-20 | 2016-09-22 | Forschungszentrum Jülich GmbH Fachbereich Patente | Spezifisch A-Beta Spezies bindende Peptide für die Therapie und/oder die Diagnose der Alzheimerschen Demenz |
| DE102016125645A1 (de) * | 2016-12-23 | 2018-06-28 | Forschungszentrum Jülich GmbH | D-enantiomere Peptide zur Therapie von chronischem und neuropathischem Schmerz |
| WO2019070645A1 (en) * | 2017-10-02 | 2019-04-11 | Cedars-Sinai Medical Center | METHODS AND COMPOSITIONS FOR EFFECTIVE ADMINISTRATION THROUGH MULTIPLE BIOLOGICAL BARRIERS |
| DE102021121435A1 (de) * | 2021-08-18 | 2023-02-23 | Priavoid Gmbh | Aß-BINDENDE SUBSTANZEN |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE355374T1 (de) | 2000-11-27 | 2006-03-15 | Praecis Pharm Inc | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen |
| WO2002081515A1 (fr) * | 2001-04-03 | 2002-10-17 | Kyowa Hakko Kogyo Co., Ltd. | Proteine de liaison de facteur de croissance de type insuline |
| DE10117281A1 (de) | 2001-04-06 | 2002-10-24 | Inst Molekulare Biotechnologie | Peptid zur Diagnose und Therapie der Alzheimer-Demenz |
| US20050158306A1 (en) * | 2004-01-16 | 2005-07-21 | Halikas James A. | Treatment for neuro-degenerative disease by a blood cleansing system using monoclonal antibodies |
| AT500483B1 (de) * | 2004-07-13 | 2006-01-15 | Mattner Frank Dr | Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung |
| US20070092508A1 (en) * | 2005-10-21 | 2007-04-26 | Recombiant Technologies, Llc | Detoxification depot for Alzheimer's disease |
| US8445438B2 (en) | 2008-10-27 | 2013-05-21 | Recombinant Technologies Llc | Compositions comprising capture peptides for A β-amyloid peptide |
| DE102008037564A1 (de) * | 2008-11-19 | 2010-05-20 | Forschungszentrum Jülich GmbH | Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden |
| DE102010017130B4 (de) | 2010-05-28 | 2018-11-29 | Forschungszentrum Jülich GmbH | Hybrid-Verbindung, deren Verwendung und Verfahren zu deren Herstellung |
| CN104380111B (zh) | 2012-04-05 | 2017-08-29 | 于利希研究中心有限公司 | 包含多价结合淀粉样β蛋白的D‑肽的聚合物及其应用 |
| DE102012108598A1 (de) * | 2012-09-14 | 2014-04-10 | Forschungszentrum Jülich GmbH | Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung |
| JP2015518474A (ja) * | 2012-04-05 | 2015-07-02 | フォルシュングスツェントルム ユーリッヒ ゲゼルシャフト ミット ベシュレンクテル ハフツングＦｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ Ｊｕｅｌｉｃｈ ＧｍｂＨ | 血液、血液生産物及び器官を処置する方法 |
-
2012
- 2012-09-14 DE DE102012108598.6A patent/DE102012108598A1/de not_active Withdrawn
-
2013
- 2013-09-13 CN CN201710944015.7A patent/CN107556375A/zh active Pending
- 2013-09-13 ES ES13776426T patent/ES2768264T3/es active Active
- 2013-09-13 PL PL17172220.0T patent/PL3346273T3/pl unknown
- 2013-09-13 EP EP13776426.2A patent/EP2895867B1/de active Active
- 2013-09-13 DK DK13776426.2T patent/DK2895867T3/da active
- 2013-09-13 DK DK17172220.0T patent/DK3346273T5/da active
- 2013-09-13 WO PCT/EP2013/068992 patent/WO2014041115A2/de not_active Ceased
- 2013-09-13 JP JP2015531567A patent/JP6345670B2/ja active Active
- 2013-09-13 ES ES17172220T patent/ES2938773T3/es active Active
- 2013-09-13 US US14/426,797 patent/US20150307552A1/en not_active Abandoned
- 2013-09-13 EP EP17172220.0A patent/EP3346273B1/de active Active
- 2013-09-13 CN CN201380047981.9A patent/CN104704371B/zh active Active
-
2017
- 2017-04-10 US US15/482,968 patent/US10167318B2/en not_active Expired - Fee Related
-
2018
- 2018-05-23 JP JP2018098517A patent/JP6611858B2/ja active Active
- 2018-11-27 US US16/200,820 patent/US10889618B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015531348A5 (enExample) | ||
| MX384227B (es) | Anticuerpos y fragmentos de unión a antígenos para usarse en el tratamiento y la profilaxis de amiloidosis. | |
| Mohajeri et al. | Carbon nanomaterials and amyloid-beta interactions: potentials for the detection and treatment of Alzheimer's disease? | |
| JP2010531992A5 (enExample) | ||
| IN2014DN05670A (enExample) | ||
| JP2009225798A5 (enExample) | ||
| AU2018201997B2 (en) | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions | |
| TWI455721B (zh) | 癌疫苗組合物 | |
| JP2010166916A5 (enExample) | ||
| MX2011010353A (es) | Composicion farmaceutica. | |
| CY1118813T1 (el) | Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων | |
| MX361728B (es) | Ácido nucleico que comprende o codifica un tallo-bucle de histona y una secuencia poli(a) o una señal de poliadenilación para incrementar la expresión de un antígeno tumoral codificado. | |
| CY1117326T1 (el) | Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson | |
| JP2017529097A5 (enExample) | ||
| JP2013520405A5 (enExample) | ||
| JP2016525095A5 (ja) | 環状ポリペプチド | |
| WO2014111458A3 (en) | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases | |
| JP2015164424A5 (enExample) | ||
| MY205948A (en) | Anti-alpha-synuclein antibodies | |
| MX2020005810A (es) | Anticuerpos anti-alfa sinucleina. | |
| EP4306123A3 (en) | Saposin-a derived peptides and uses thereof | |
| JP2019513752A5 (enExample) | ||
| BR112013032088A2 (pt) | "polipeptídeo, composição farmacêutica e seu uso" | |
| JP2016539911A5 (enExample) | ||
| EA202190310A1 (ru) | Белок для лечения воспалительных заболеваний |